Moderna (Nasdaq:MRNA) - Stock Price, News & Analysis

MRNA Stock Overview

MRNA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 48% below our estimate of its fair value

Risk Analysis

No risks detected for MRNA from our risk checks.

Moderna, Inc. Competitors

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Alnylam Pharmaceuticals

NasdaqGS:ALNY

US$21.1b

BioNTech

NasdaqGS:BNTX

US$23.9b

BeiGene

NasdaqGS:BGNE

US$19.5b

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share Price	US$79.83
52 Week High	US$217.25
52 Week Low	US$62.55
Beta	1.7
1 Month Change	4.76%
3 Month Change	-29.08%
1 Year Change	-56.22%
3 Year Change	-47.66%
5 Year Change	329.19%
Change since IPO	329.19%

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03

Recent updates

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 18

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

May 23

Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Mar 03

Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% Dive

Feb 25

Moderna gets EMA review for Omicron BA.4/BA.5 targeting booster shot for aged 12, above

Sep 28

EMA aims to start review of Moderna's Omicron BA.4/5 adapted shot by end of September

Sep 20

Moderna CEO open to providing COVID shots to China; mulls building mRNA facility in Japan - Reuters

Sep 14

Pfizer/BioNTech's Omicron-targeting booster vaccine gets approval in UK

Sep 05

Shareholder Returns

	MRNA	US Biotechs	US Market
7D	1.7%	2.9%	1.1%
1Y	-56.2%	-7.7%	11.9%

Return vs Industry: MRNA underperformed the US Biotechs industry which returned -7.7% over the past year.

Return vs Market: MRNA underperformed the US Market which returned 11.9% over the past year.

Price Volatility

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement	7.0%
Biotechs Industry Average Movement	11.4%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: MRNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: MRNA's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2010	3,900	Stephane Bancel	https://www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
MRNA fundamental statistics
Market Cap	US$29.63b
Earnings (TTM)	-US$3.47b
Revenue (TTM)	US$9.12b

3.3x

P/S Ratio

-8.8x

P/E Ratio

Is MRNA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRNA income statement (TTM)
Revenue	US$9.12b
Cost of Revenue	US$10.33b
Gross Profit	-US$1.21b
Other Expenses	US$2.26b
Earnings	-US$3.47b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-9.09
Gross Margin	-13.28%
Net Profit Margin	-38.00%
Debt/Equity Ratio	0%

How did MRNA perform over the long term?

See historical performance and comparison

MRNA Stock Overview

Rewards

Risk Analysis

Moderna, Inc. Competitors

NasdaqGS:HZNP

US$26.6b

NasdaqGS:ALNY

US$21.1b

NasdaqGS:BNTX

US$23.9b

NasdaqGS:BGNE

US$19.5b

Price History & Performance

Recent News & Updates

Consensus EPS estimates fall by 199%

Moderna, Inc. Provides Sales Guidance for the Year 2023

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Price target decreased by 11% to US$155

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Recent updates

Consensus EPS estimates fall by 199%

Moderna, Inc. Provides Sales Guidance for the Year 2023

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Price target decreased by 11% to US$155

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Investor sentiment deteriorates as stock falls 17%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Co-Founder notifies of intention to sell stock

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Investor sentiment improves as stock rises 21%

President notifies of intention to sell stock

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Consensus EPS estimates fall by 50%

Price target decreased by 7.2% to US$185

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Consensus EPS estimates fall by 12%

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Consensus EPS estimates fall by 10%

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings released: EPS: US$0.20 (vs US$9.10 in 1Q 2022)

Consensus EPS estimates upgraded to US$1.69 loss

CEO & Director exercised options and sold US$12m worth of stock

CEO & Director notifies of intention to sell stock

Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Consensus EPS estimates have been downgraded.

Now 21% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% Dive

Full year 2022 earnings: EPS misses analyst expectations

CEO & Director notifies of intention to sell stock

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

CEO & Director exercised options and sold US$13m worth of stock

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

CEO & Director exercised options and sold US$15m worth of stock

CEO & Director exercised options and sold US$16m worth of stock

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

CEO & Director exercised options and sold US$15m worth of stock

CEO & Director notifies of intention to sell stock

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Investor sentiment deteriorated over the past week

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week